Biogen extends Ionis deal in SMA
Biogen (Nasdaq: BIIB) is to pay $25 million upfront to Ionis Pharmaceuticals (Nasdaq: IONS) as part of an expansion of their collaboration to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy (SMA).
The US companies are already partners in a number of strategic alliances, including over the development and commercialization of Spinraza (nusinersen), which gained US approval in December 2016 to treat pediatric and adult patients with SMA.
This new deal will also see Biogen having the option to license therapies arising out of the collaboration, and it will be responsible for their development and commercialization and must pay milestone sums to Ionis, as well as further payments and royalties on any sales achieved.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze